JAMES HOPPER: Open Payments
NPI 1144306283 · AMSTERDAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$319 in 16 payments from 9 companies in 2025. Trend: 2023 $275 · 2024 $518 · 2025 $319
Food & beverage: $319
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $80 |
| Amgen Inc. | 3 | $47 |
| GlaxoSmithKline, LLC. | 2 | $46 |
| ABBVIE INC. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
| Dexcom, Inc. | 1 | $23 |
| Exeltis, USA Inc. | 1 | $21 |
| PFIZER INC. | 1 | $20 |
| Renalytix AI, Inc. | 1 | $14 |
Products named: Ozempic, OTEZLA, QULIPTA, AIRSUPRA, BEXSERO, Dexcom G6 Transmitter, SHINGRIX, SLYND.
Industry payments across NY — which companies pay providers there.
